BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17008533)

  • 21. Modeling acute promyelocytic leukemia in the mouse: new insights in the pathogenesis of human leukemias.
    Merghoub T; Gurrieri C; Piazza F; Pandolfi PP
    Blood Cells Mol Dis; 2001; 27(1):231-48. PubMed ID: 11358384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of
    Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
    J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance.
    Hussain L; Maimaitiyiming Y; Islam K; Naranmandura H
    Semin Oncol; 2019 Apr; 46(2):133-144. PubMed ID: 31126665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia.
    Schoch C; Schnittger S; Kern W; Lengfelder E; Löffler H; Hiddemann W; Haferlach T
    Hematol J; 2002; 3(5):259-63. PubMed ID: 12391544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PML-RARα stabilized by zinc in human acute promyelocytic leukemia NB4 cells.
    Zhu B; Wang JY; Zhou JJ; Zhou F; Cheng W; Liu YT; Wang J; Chen X; Chen DH; Luo L; Hua ZC
    J Inorg Biochem; 2017 Oct; 175():92-100. PubMed ID: 28743050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B.
    Wang C; Su L; Shao YM; Chen WZ; Bu N; Hao R; Ma LY; Hussain L; Lu XY; Wang QQ; Naranmandura H
    Toxicol Appl Pharmacol; 2019 Dec; 384():114775. PubMed ID: 31669778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models.
    Rego EM; Pandolfi PP
    Semin Hematol; 2001 Jan; 38(1):54-70. PubMed ID: 11172540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PML-RAR{alpha} and Dnmt3a1 cooperate in vivo to promote acute promyelocytic leukemia.
    Subramanyam D; Belair CD; Barry-Holson KQ; Lin H; Kogan SC; Passegué E; Blelloch R
    Cancer Res; 2010 Nov; 70(21):8792-801. PubMed ID: 20861188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constitutive expression of the promyelocytic leukemia-associated oncogene PML-RARalpha in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis.
    Slack JL; Yu M
    Blood; 1998 May; 91(9):3347-56. PubMed ID: 9558392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External quality assessment for PML-RARα detection in acute promyelocytic leukemia: Findings and summary.
    Wu Q; Zhang R; Fu Y; Zhang J; Chen K; Li J
    J Clin Lab Anal; 2019 Jul; 33(6):e22894. PubMed ID: 31131502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures.
    Walter MJ; Park JS; Lau SK; Li X; Lane AA; Nagarajan R; Shannon WD; Ley TJ
    Mol Cell Biol; 2004 Dec; 24(24):10882-93. PubMed ID: 15572690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.
    Voisset E; Moravcsik E; Stratford EW; Jaye A; Palgrave CJ; Hills RK; Salomoni P; Kogan SC; Solomon E; Grimwade D
    Blood; 2018 Feb; 131(6):636-648. PubMed ID: 29191918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia.
    Kitamura K; Kiyoi H; Yoshida H; Saito H; Ohno R; Naoe T
    Leukemia; 1997 Nov; 11(11):1950-6. PubMed ID: 9369431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pro-proliferative function of the long isoform of PML-RARalpha involved in acute promyelocytic leukemia.
    Tussié-Luna MI; Rozo L; Roy AL
    Oncogene; 2006 Jun; 25(24):3375-86. PubMed ID: 16434964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The theory of APL.
    Piazza F; Gurrieri C; Pandolfi PP
    Oncogene; 2001 Oct; 20(49):7216-22. PubMed ID: 11704849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.
    Gupta V; Yib QL; Brandwein J; Chun K; Lipton JH; Messner H; Schuh AC; Wells RA; Minden MD; Kamel-Reidc S
    Leuk Lymphoma; 2004 Mar; 45(3):469-80. PubMed ID: 15160908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia.
    Takayama N; Kizaki M; Hida T; Kinjo K; Ikeda Y
    Exp Hematol; 2001 Jul; 29(7):864-72. PubMed ID: 11438209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells.
    Fu S; Consoli U; Hanania EG; Zu Z; Claxton DF; Andreeff M; Deisseroth AB
    Clin Cancer Res; 1995 Jun; 1(6):583-90. PubMed ID: 9816019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of Different PML/RARα bcr Isoforms in Indian Acute Promyelocytic Leukemia (APL) Patients and Clinicohematological Correlation.
    Chatterjee T; Gupta S; Sharma S; Ganguli P
    Mediterr J Hematol Infect Dis; 2014 Jan; 6(1):e2014004. PubMed ID: 24455113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.